Swedish Metals and Mining Stock News

In January 2026, TF Bank AB (publ) reported full-year 2025 results showing higher net interest income of SEK 2,678.96 million and net income of SEK 667.05 million, alongside basic and diluted earnings per share of SEK 9.92. The Board also proposed a dividend of SEK 5.00 per share for 2025, signaling confidence in the bank’s ability to return capital to shareholders from its recent performance. With this combination of rising earnings and a proposed SEK 5.00 dividend, we’ll examine how TF...

Why the FDA review of Oclaiz matters for Camurus The fresh interest in Camurus (OM:CAMX) centers on the FDA’s decision to accept for review the resubmitted New Drug Application for Oclaiz, its extended release octreotide injection for acromegaly. This follows marketing authorization and an early launch in the EU and UK under the name Oczyesa, and it gives investors a clearer timetable, with a PDUFA target action date set for 10 June 2026. See our latest analysis for Camurus. The FDA review...

Cibus Nordic Real Estate AB (publ) has completed a refinancing move, issuing €85 million of new floating rate senior unsecured green notes due 2030 and confirming the unconditional early redemption of its initial €50 million green notes at 101.25% plus accrued interest, with settlement on 4 February 2026. This refinancing reshapes Cibus’ debt profile by replacing an earlier green bond with a larger, longer-dated issue, potentially enhancing financial flexibility and reinforcing its...

Elekta (OM:EKTA B) has attracted fresh attention after its Elekta Evo CT-Linac received FDA 510(k) clearance, opening the door for U.S. adoption of its AI supported imaging and radiation therapy platform. See our latest analysis for Elekta. The FDA clearance arrives at a time when Elekta’s share price has a 90 day share price return of 20.20% and a 30 day share price return of 6.47%, while the 1 year total shareholder return of a 2.89% decline and 5 year total shareholder return of a 40%...

Embracer Group (OM:EMBRAC B) has appointed long time games and entertainment executive Lee Guinchard as Chief Operating Officer, expanding his remit as the company reshapes itself into Fellowship Entertainment and refines how it uses key franchises. See our latest analysis for Embracer Group. Guinchard’s appointment comes after a difficult period for investors, with the share price at SEK 49.21 and a 90 day share price return showing a 52.24% decline, while the 1 year total shareholder return...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Most readers would already be aware that Hexatronic Group's (STO:HTRO) stock increased significantly by 13% over the...

Key Insights Hoist Finance's significant private companies ownership suggests that the key decisions are influenced by...

With its stock down 3.4% over the past week, it is easy to disregard Nolato (STO:NOLA B). However, the company's...

The board of Telia Company AB (publ) ( STO:TELIA ) has announced that it will pay a dividend on the 11th of February...

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Key Insights The considerable ownership by private companies in Fastighets AB Balder indicates that they collectively...

The European market has shown resilience, with the STOXX Europe 600 Index gaining ground thanks to robust economic data and encouraging earnings results. Amid this backdrop, penny stocks—though often associated with speculative trading—remain a relevant investment area when backed by solid financials. These smaller or newer companies can offer a unique blend of affordability and growth potential, making them attractive options for investors seeking opportunities beyond the mainstream.

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Cheffelo's (STO:CHEF) stock is up by a considerable 24% over the past month. As most would know, fundamentals are what...

Key Insights Significant control over Volati by individual investors implies that the general public has more power to...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Invisio fair value estimate is kr403 Invisio's kr313 share...

Key Insights Lifco's significant insider ownership suggests inherent interests in company's expansion The largest...

To the annoyance of some shareholders, Acuvi AB ( STO:ACUVI ) shares are down a considerable 26% in the last month...

Gruvaktiebolaget Viscaria ( STO:VISC ) shareholders are no doubt pleased to see that the share price has bounced 41% in...

Camurus AB (publ) recently announced that the U.S. FDA has accepted for review its resubmitted New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly, with a PDUFA target action date set for 10 June 2026. This acceptance helps clear a prior hurdle tied to third-party manufacturing observations and follows earlier EU and UK approvals and launch of the same product, marketed there as Oczyesa. We will now examine how FDA acceptance of the Oclaiz...

When close to half the companies in Sweden have price-to-earnings ratios (or "P/E's") below 22x, you may consider Sweco...

Investment AB Latour (publ) ( STO:LATO B ) saw significant share price movement during recent months on the OM, rising...